Partner with us to advance IMYX-3

Immunyx Pharma is advancing IMYX-3, our lead program for ulcerative colitis, a chronic inflammatory bowel disease where patients still need more effective and more durable treatment options. We are open to partnerships with pharmaceutical companies that can help bring IMYX-3 to the patients who need it.

What we’re looking for

We welcome discussions on a range of collaboration structures, including:

• Co-development and co-commercialization of IMYX-3 in ulcerative colitis
• Licensing or regional partnerships
• Development in additional neutrophil-mediated indications beyond ulcerative colitis, including Hidradenitis Suppurativa

Let’s talk

If your organization is exploring opportunities in ulcerative colitis or related inflammatory diseases, we’d welcome the conversation. Contact us at  info@immunyx.com to discuss how we might work together.